Medical Devices India

India Pharmacogenomic Testing for Psychiatry Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

India Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $9.3 Mn Placeholder estimate
Estimate 2025 $10.5 Mn 2.2% of the global market
Projected 2034 $32.4 Mn 207.7% Adds $21.9 Mn over 9 forecast years
CAGR 2025–2034 13.3% Faster than 64% of 173 Medical Devices markets here
Key players 5
  • India is 2.17% of the global market.
  • In APAC, the largest is China at $42.4 Mn.
  • Fastest growing: India (this report) at 13.3% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$21.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing for Psychiatry Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $9.3 Mn — —
2025 (base) $10.5 Mn +$1.2 Mn —
2026 (forecast) $11.9 Mn +$1.4 Mn +13.3%
2027 (forecast) $13.5 Mn +$1.6 Mn +28.4%
2028 (forecast) $15.3 Mn +$1.8 Mn +45.4%
2029 (forecast) $17.3 Mn +$2.0 Mn +64.8%
2030 (forecast) $19.7 Mn +$2.3 Mn +86.7%
2031 (forecast) $22.3 Mn +$2.6 Mn +111.5%
2032 (forecast) $25.2 Mn +$3.0 Mn +139.7%
2033 (forecast) $28.6 Mn +$3.4 Mn +171.5%
2034 (forecast) $32.4 Mn +$3.8 Mn +207.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Pharmacogenomic Testing for Psychiatry Market Analysis at a glance
Market size, 2025$10.5 Mn placeholder estimate
Forecast, 2034$32.4 Mn placeholder estimate
Growth (CAGR), 2025–203413.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., Genomind, OneOme, Tempus, Thermo Fisher Scientific Inc. (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Pharmacogenomic Testing for Psychiatry Market Analysis Executive Summary

Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.

Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).

Bar chart: India Pharmacogenomic Testing for Psychiatry market size, 2024–2034, placeholder estimates. $9.3 Mn in 2024, $10.5 Mn in 2025 and $32.4 Mn in 2034, 13.3% CAGR.
India Pharmacogenomic Testing for Psychiatry market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Pharmacogenomic Testing for Psychiatry Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.

Competitive Landscape for Pharmacogenomic Testing for Psychiatry Market in India

The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing for Psychiatry Market in India

Pharmacogenomic Testing for Psychiatry in India: rules, payment and health figures

Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2] Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure for India.⁠[3]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing for Psychiatry right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing for Psychiatry in context

India compared

  • Suicide rate: 14.0 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). 2nd highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing for Psychiatry market in India?
Placeholder estimate: about $10.5 Mn in 2025, rising to about $32.4 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing for Psychiatry market in India growing?
Placeholder estimate: about 13.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing for Psychiatry market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Depression, Anxiety, ADHD, Bipolar Disorder) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing for Psychiatry market?
Key players include Myriad Genetics, Inc., Genomind, OneOme, Tempus and Thermo Fisher Scientific Inc..
What is driving the Pharmacogenomic Testing for Psychiatry market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Who regulates Pharmacogenomic Testing for Psychiatry in India?
Since October 2023, every medical device sold in India needs a licence under the Medical Devices Rules, 2017, from the Central Drugs Standard Control Organisation (CDSCO) or, for some lower-risk devices made in India, a state authority. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
What does WHO report for India?
Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in India are 65 or older?
7.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.
How much research is published on Pharmacogenomic Testing for Psychiatry?
PubMed lists 6 papers on Pharmacogenomic Testing for Psychiatry added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in India

See all

Related on mental health and genomics

See the topic